Breaking News Instant updates and real-time market news.

GREK

Global X MSCI Greece ETF

, HEDJ

WisdomTree Europe Hedged Equity Fund

09:40
12/01/17
12/01
09:40
12/01/17
09:40

Unusually active option classes on open December 1st

Unusual total active option classes on open include: GlobalFTSE Greece (GREK), Wizdom Tree Europe (HEDJ), KeyCorp (KEY), Ambarella (AMBA), Ulta Beauty (ULTA), Market Vectors Oil Services (OIH), Altria Group (MO), Cliffs Natural (CLF), General Motors (GM), and Boeing (BA).

GREK

Global X MSCI Greece ETF

HEDJ

WisdomTree Europe Hedged Equity Fund

KEY

KeyCorp

AMBA

Ambarella

$54.27

-0.19 (-0.35%)

ULTA

Ulta Beauty

$221.71

-1.39 (-0.62%)

OIH

Oil Services Holders Trust

MO

Altria Group

CLF

Cleveland-Cliffs

GM

General Motors

BA

Boeing

  • 09

    Jan

  • 16

    Jan

  • 18

    Jan

GREK Global X MSCI Greece ETF

HEDJ WisdomTree Europe Hedged Equity Fund

KEY KeyCorp

09/27/17
DADA
09/27/17
NO CHANGE
DADA
KeyCorp named top large bank at DA Davidson
DA Davidson analyst Kevin K. Reevey says that KeyCorp is "one of the least expensive names" he covers, while it is continuing to benefit a great deal from its takeover of First Niagara last year. The analyst thinks that the bank's stock can rise as it "continues to execute according to plan," and he identifies it as his favorite large-cap bank stock.
09/14/17
BERN
09/14/17
UPGRADE
BERN
Outperform
KeyCorp upgraded to Outperform at Bernstein
As previously reported, Bernstein analyst Kevin St. Pierre upgraded KeyCorp (KEY) to Outperform from Market Perform as he believes there is more likely to be upside to his 2018-2020 estimates than downside. With the year to date underperformance of the stock, the analyst believes valuation is far more attractive than at the start of the year. St. Pierre also upgraded Citizens Financial (CFG) and Huntington Bancshares (HBAN) to Outperform.
10/26/17
BMOC
10/26/17
DOWNGRADE
Target $14.5
BMOC
Market Perform
Huntington downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Lana Chan downgraded Huntington Bancshares (HBAN) to Market Perform citing slower near-term loan growth and "continued disappointment" on operating expenses following the company's Q3 results. The analyst lowered her price target for the shares to $14.50 from $15. Chan's top picks are now KeyCorp (KEY) and Signature Bank (SBNY).
11/15/17
MSCO
11/15/17
NO CHANGE
MSCO
Morgan Stanley says higher SIFI threshold could benefit Comerica, CIT, Zions
After Senate Banking Committee Chairman Mike Crapo proposed a bill in the Senate that would effectively remove the SIFI threshold for banks under $250B, Morgan Stanley analyst Ken Zerbe estimated that banks with $50B-$100B in assets could see a 12% increase in 2020 EPS and a 15% bump in 2021. He sees the largest potential increase at Comerica (CMA), followed by CIT Group (CIT) and Zions Bancorp (ZION). Zerbe projects the least EPS benefit for SunTrust (STI), Regions Financial (RF), Ally Financial (ALLY) and Discover (DFS), he tells investors. Other banks he lists in his note as potentially impacted by SIFI and CCAR changes include Synchrony (SYF), M&T Bank (MTB), KeyCorp (KEY), Fifth Third (FITB), BB&T (BBT), Citizens Financial (CFG) and Huntington Bancshares (HBAN).
AMBA Ambarella
$54.27

-0.19 (-0.35%)

10/13/17
ADAM
10/13/17
NO CHANGE
Target $65
ADAM
Buy
Ambarella share price undervalues computer vision IP, says Canaccord
Canaccord analyst Matthew Ramsay noted Ambarella shares have been volatile since its last earnings report and he believes the bumps are likely to remain over the near-term. However, he believes the challenges have caused investors to undervalue its long-term computer vision hardware and software intellectual property and growth potential in more stable security and automotive markets. Ramsay reiterated his Buy rating and raised his price target to $65 from $58 on Ambarella shares.
09/27/17
MSCO
09/27/17
NO CHANGE
Target $60
MSCO
Overweight
Morgan Stanley ups Ambarella 'bull case' to $115 on computer vision opportunity
Morgan Stanley analyst Joseph Moore said that after spending three days on a road show with Ambarella management he came away with more appreciation for the potential of the company's computer vision opportunity, where it could become a market leader. If early company claims prove accurate, he sees a "bull case" for the stock up to $115, though he cautions that even in the bull case revenue traction in ADAS will likely take multiple years. The analyst, who has a $60 base case price target on Ambarella, keeps an Overweight rating on the shares.
12/01/17
MSCO
12/01/17
NO CHANGE
Target $60
MSCO
Overweight
Ambarella commentary on computer vision 'notably stronger,' says Morgan Stanley
Morgan Stanley analyst Joseph Moore said Ambarella's commentary on its computer vision chip was notably stronger and he expects to get much more detail in the coming months, pointing to January's Consumer Electronics Show as an important upcoming catalyst. Ambarella management said they had sampled the first version of the CV chip to automotive and surveillance customers and there is a possibility they could announce auto development relationships for CV in 2018, maybe even the first half of the year, noted Moore, who maintains an Overweight rating and $60 price target on Ambarella shares.
12/01/17
ADAM
12/01/17
NO CHANGE
Target $67
ADAM
Buy
Ambarella share price undervalues computer vision IP, says Canaccord
Canaccord analyst Matthew Ramsay noted Ambarella reported solid Q3 results driven by strength in several end markets including both professional and home security, automotive, and wearable cameras. The analyst believes that although near-term bumps remain, the current share price undervalues the company's computer vision IP, growth potential, and engineering teams. Ramsay reiterated his Buy rating and raised his price target to $67 form $65 on Ambarella shares.
ULTA Ulta Beauty
$221.71

-1.39 (-0.62%)

12/01/17
RBCM
12/01/17
NO CHANGE
Target $225
RBCM
Sector Perform
Ulta Beauty price target lowered to $225 from $250 at RBC Capital
RBC Capital analyst Brian Tunick lowered his price target on Ulta Beauty to $225 after yesterday's earnings, saying that while comps were in line with lowered expectations, the gross margin decline was the "sticking point" of the report amid unfavorable product shift and loyalty program promotions. Tunick keeps his Sector Perform rating, noting that although the company can maintain its EPS growth rate, the upside in the stock may be limited on slowing fundamentals of beauty product category growth.
12/01/17
WELS
12/01/17
NO CHANGE
Target $220
WELS
Market Perform
Ulta Beauty price target lowered to $220 from $242 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for Ulta Beauty to $220 saying that while the Q3 comps were "robust" once again, last night marked the second straight quarter the company did not beat its comp plan. The analyst, however, believes the larger issue is Ulta missing its gross margin plan for the third time in the past four quarters. The shares will remain "under some pressure as the market grapples with how to value this growth story which is clearly transitioning into a more stable profile," Boruchow tells investors in a post-earnings research note. He keeps a Market Perform rating on Ulta Beauty.
12/01/17
JPMS
12/01/17
NO CHANGE
Target $270
JPMS
Overweight
JPMorgan sees only 'modest pressure' for Ulta Beauty shares
JPMorgan analyst Christopher Horvers believes shares of Ulta Beauty will only see "modest pressure" today given that the company reported better than guided comps ex-hurricane in Q3 and provided an outlook for relatively improved merchandise margin performance. Further, management re-committed to 20%-plus earnings growth in 2018, Horvers tells investors in a post-earnings research note. He believes these "will likely stave off what could have been a tough day for the stock" given the 110 basis point decline in gross margin for Q3. The analyst keeps an Overweight rating on Ulta Beauty with a $270 price target. The shares in premarket trading are down 6% to $207.66.
12/01/17
MSCO
12/01/17
NO CHANGE
Target $235
MSCO
Equal Weight
Ulta Beauty price target lowered to $235 after 'mixed bag' Q3 at Morgan Stanley
Morgan Stanley analyst Simeon Gutman said Ulta Beauty offered a "mixed bag" in terms of its Q3 results, with in-line comparable sales growth but much weaker gross margins than it has had in some time. The analyst, who said competitive pressures seem to be intensifying, lowered his price target on Ulta to $235 from $245 and keeps an Equal Weight rating on the shares.
OIH Oil Services Holders Trust

MO Altria Group

10/06/17
WELS
10/06/17
NO CHANGE
WELS
Nicotine study could pressure tobacco stocks, says Wells Fargo
Dr. Dorothy Hatsukami's 1,250 patient, 20 week Phase III study, which suggested an immediate reduction in nicotine levels by the FDA would be more effective than a gradual reduction in terms of discouraging compensatory behavior, could create near-term headline risk for tobacco stocks, Wells Fargo analyst Bonnie Herzog tells investors in an intraday research note after XXII Century Group announced the results. Investors may worry the data could precipitate sharper declines in combustible cigarette volumes, the analyst contends. She continues to believe, however, that such an outcome would only accelerate conversion to reduced-risk products such as iQOS, which she notes does not appear to have been a part of the study. Publicly traded companies in the tobacco space include Altria Group (MO), British American Tobacco (BTI) and Philip Morris (PM).
10/02/17
WELS
10/02/17
UPGRADE
WELS
Outperform
Great Plains Energy upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Sarah Akers upgraded both Great Plains Energy (GXP) and Westar Energy (WR) to Outperform saying the merger has a high likelihood of regulatory approval. The analyst believes the shares are "modestly undervalued" and sees further upside potential should Altria Group (MO) and/or KapStone (KS) become "more supportive of new investments over time." Akers has a $33 price target for Great Plains shares.
09/28/17
WELS
09/28/17
NO CHANGE
WELS
Wells Fargo recommends buying Altria Group ahead of catalysts
Wells Fargo notes that Altria Group's stock has pulled back sharply since the FDA's announcement and has remained pressured given concerns about Marlboro share softness and volume trends. The firm says its valuation is now at a 2-year low, reflecting minimal credit for potential U.S. corporate tax reform which could lower the top rate to 25%, increased leverage and stepped up buybacks, U.S. commercialization of iQOS as soon as February 2018, and/or further industry consolidation. Wells Fargo urges long-term investors to build positions and believes the risk/reward is favorable ahead of the company's Q3 results.
09/26/17
09/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Discovery (DISCA) upgraded to Neutral from Sell at UBS with analyst Doug Mitchelson saying the risk/reward is balanced with the shares down 22% year-to-date. 2. Altria Group (MO) upgraded to Outperform from Market Perform at Cowen with analyst Vivien Azer citing its notable pullback following the late July FDA announcement and a bigger than expected price increase which reinforces the durability of its earnings growth. 3. L Brands (LB) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying recent Victoria Secret visits are highly encouraging with a number of changes that should drive a positive inflection in comps over the next several months. 4. Boston Beer (SAM) upgraded to Neutral from Underperform at Credit Suisse with analyst Laurent Grandet saying the market sentiment remains "overly negative," which creates a more balanced spread between upside and downside scenarios. 5. British American Tobacco (BTI) upgraded to Outperform from Market Perform at Cowen with analyst Vivien Azer saying she views the weakness from FDA risk and foreign exchange movements as having created an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CLF Cleveland-Cliffs

07/31/17
AXIO
07/31/17
NO CHANGE
AXIO
Sell
Axiom says 'now is the time' to short U.S. Steel, maintains Sell rating
Axiom analyst Gordon Johnson II believes "now is the time" to short U.S. Steel (X) and Cliffs Natural (CLF) shares and to go underweight the U.S. steel sector, as he sees an increasing likelihood of an indefinite delay in the US Commerce Department's 232 steel tariff decision. He also thinks the contribution to China's GDP growth from commodity-intensive sectors may have peaked, he tells investors. The analyst keeps a Sell rating on U.S. Steel shares.
04/28/17
04/28/17
UPGRADE

Outperform
Cliffs Natural upgraded to Outperform from Market Perform at FBR Capital
09/25/17
MSCO
09/25/17
NO CHANGE
MSCO
Morgan Stanley raising price targets on Metals & Mining stocks
Morgan Stanley analyst Piyush Sood is "more constructive" in his outlook for base metals and met coal stocks and raised his price targets on Alcoa (AA) to $54 from $47, Freeport-McMoRan (FCX) to $10 from $8, Teck Resources (TECK) to $20 from $17, Newmont Mining (NEM) to $33 from $31, and Warrior Met Coal (HCC) to $22 from $17. Sood added that Alcoa remains his top pick. However, Sood lowered the price target of Cleveland-Cliffs (CLF) to $7 from $8.
10/23/17
JPMS
10/23/17
DOWNGRADE
Target $7
JPMS
Neutral
Cleveland-Cliffs downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Gambardella downgraded Cleveland-Cliffs to Neutral citing lower U.S. iron ore prices following the company's Q3 results. The analyst dropped his price target for the shares to $7.00 from $9.50.
GM General Motors

12/01/17
DBAB
12/01/17
NO CHANGE
Target $52
DBAB
Buy
GM shares price in very little for mobility business, says Deutsche Bank
Deutsche Bank analyst Rod Lache says that if General Motors' autonomous mobility plans come to fruition, it could have "profound implications across many Industries." Following yesterday's event, the analyst continues to believe that very little of the mobility business is reflected in GM shares. His $52 price target assumes "just" $10 for GM's autonomous mobility business. The U.S. business alone could conservatively be worth at least $20 per share, and on a global basis it could be worth $40 per share, Lache tells investors in a research note. He keeps a Buy rating on GM.
12/01/17
SBSH
12/01/17
NO CHANGE
Target $60
SBSH
Buy
Citi more confident in $134 long-term upside case for GM shares
Citi analyst Itay Michaeli says he left General Motors' investor event yesterday with greater conviction on his thesis and prior $134 long-term potential upside case for the stock. The analyst attributes yesterday's share pullback to some "sell the news" and mixed feedback from media test rides in the GM autonomous vehicles, which the analyst views as a "non-issue." He believes GM's event essentially introduced a new industry, autonomous urban networks, that's moving quickly towards commercialization. He sees the market as having a significant total addressable market of "well into hundreds of billions, or higher." Michaeli thinks GM shares "stand to re-rate meaningfully higher." He keeps a Buy rating on the stock with a $60 price target.
12/01/17
LEHM
12/01/17
NO CHANGE
Target $57
LEHM
Overweight
Barclays ups GM price target to $57 after tech day
Barclays analyst Brian Johnson raised his price target for General Motors (GM) to $57 from $55 following yesterday's tech day. The automaker closed yesterday down 72c to $43.09. While some view GM's target of commercially launching at scale autonomous ridesharing in dense urban environments in 2019 as an unrealistic target, similar to the timelines pushed by Tesla (TLSA), time with management indicated this seems possible, Johnson tells investors in a research note. GM's technology is real, and the company has a fail-safe with the autonomous vehicles to be monitored by humans at control centers, the analyst contends. The tech day reinforced Johnson's view that GM has first mover advantage in mobility. He believes the shares are due for a "multiple re-rating" and reiterates an Overweight rating on GM.
11/28/17
MSCO
11/28/17
NO CHANGE
Target $43
MSCO
Equal Weight
GM may have hard time exceeding autonomous expectations, says Morgan Stanley
Ahead of General Motors' autonomous car events on November 29 and 30, Morgan Stanley analyst Adam Jonas said the company may find it difficult to top the rising expectations for its leadership in this "hotly contested" area. Investor sentiment around GM "vastly exceeds" where it was earlier this year, both because the company has executed and the global light vehicle market has held up better than expected, but also because the company has changed the narrative of the company's future to one where it can exert leadership in key areas such as shared mobility, connected and electric cars and autonomous vehicles, Jonas tells investors. He thinks GM will give a timeline for deploying fully autonomous fleets in a service within quarters, not years, but also believes its autonomous driving efforts are more likely to be a modest drag on earnings than a benefit for some years to come. Jonas keeps an Equal Weight rating and $43 price target on GM shares.
BA Boeing

10/27/17
ARGS
10/27/17
NO CHANGE
ARGS
Boeing price target raised to $290 from $270 at Argus
Argus analyst John Eade raised his price target of Boeing to $290 from $270 and maintained a Buy rating on shares, highlighting the company's Q3 results beating consensus, management raising its FY17 guidance, as well as recently raising the dividend 30%, and noting the stock's strong gain of 22% over the past quarter.
10/26/17
COWN
10/26/17
NO CHANGE
Target $315
COWN
Outperform
Boeing remains a top pick at Cowen following Q3 report
Cowen analyst Cai von Rumohr said Boeing remains his number one pick following its Q3 reports. The analyst said the company is in an extended execution sweet spot, which could boost earnings into 2020. He also sees beat and raise potential from 787 block extensions and said the shares remain cheap relative to cash flow. The analyst reiterated his Outperform rating and $315 price target on Boeing shares.
10/26/17
JPMS
10/26/17
NO CHANGE
Target $300
JPMS
Overweight
Boeing shares remain attractive, says JPMorgan
JPMorgan analyst Seth Seifman says he fielded several questions about Boeing's selloff yesterday but did not find a great answer other than the Q3 results reinforced the outlook, as opposed to the Q2 results dramatically improving it, and the stock's good performance year-to-date. The analyst believes the shares remain attractive based on the strength of the commercial aerospace end market, "visible" cash flow growth, and a "reasonable" free cash flow yield. Seifman maintains an Overweight rating on Boeing with a $300 price target.
11/21/17
JEFF
11/21/17
NO CHANGE
Target $312
JEFF
Buy
Boeing free cash flow should drive shares higher, says Jefferies
Jefferies analyst Sheila Kahyaoglu says "robust" demand for commercial aircraft and higher productivity give her increased confidence that Boeing can grow earnings at a low double-digit rate. Improved cash margins could lead to over $21 per share of free cash flow by 2020, Kahyaoglu tells investors in a research note titled "Cash Should Lead the Shares Higher." The analyst raised her price target for Boeing shares to $312 from $300 and keeps a Buy rating on the name. The plane maker closed yesterday up $2.37 to $264.63.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

20:03
12/17/17
12/17
20:03
12/17/17
20:03
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

VIA

Viacom

$34.40

0.25 (0.73%)

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

ALK

Alaska Air

$70.83

1.44 (2.08%)

ORCL

Oracle

$48.30

-1.89 (-3.77%)

HUM

Humana

$253.64

3.03 (1.21%)

KND

Kindred Healthcare

$8.60

0.45 (5.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

  • 08

    Feb

  • 08

    Feb

CME

CME Group

$151.07

0.65 (0.43%)

19:31
12/17/17
12/17
19:31
12/17/17
19:31
Periodicals
CME becomes second exchange to launch bitcoin futures, Reuters says »

CME Group became the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$19.04

0.38 (2.04%)

19:10
12/17/17
12/17
19:10
12/17/17
19:10
Hot Stocks
Spectrum Pharmaceuticals terminates Rajesh Shrotriya from CEO position »

Spectrum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SO

Southern Company

$51.31

-0.21 (-0.41%)

18:58
12/17/17
12/17
18:58
12/17/17
18:58
Hot Stocks
Georgia Power expects power to be restored by midnight tonight »

Georgia Power continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$43.08

0.74 (1.75%)

, XOM

Exxon Mobil

$83.03

0.13 (0.16%)

18:29
12/17/17
12/17
18:29
12/17/17
18:29
Periodicals
BHP, Esso to separately market Gippsland Basin gas, Reuters says »

The Australian…

BHP

BHP Billiton

$43.08

0.74 (1.75%)

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

17:48
12/17/17
12/17
17:48
12/17/17
17:48
Hot Stocks
Bombardier wins contract to provide Melbourne high-capacity signaling system »

Bombardier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$90.25

0.6 (0.67%)

, CMCSA

Comcast

$39.71

0.59 (1.51%)

17:38
12/17/17
12/17
17:38
12/17/17
17:38
Hot Stocks
Box Office Battle: 'Star Wars: The Last Jedi'' opens to $220M in U.S. »

Disney (DIS) and…

TWX

Time Warner

$90.25

0.6 (0.67%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

SNE

Sony

$44.84

0.39 (0.88%)

FOX

21st Century Fox

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

LGF.A

Lionsgate

$32.99

0.49 (1.51%)

DIS

Disney

$111.27

0.7 (0.63%)

VIAB

Viacom

$30.24

0.53 (1.78%)

VIA

Viacom

$34.40

0.25 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

EQIX

Equinix

$457.85

-2.5 (-0.54%)

17:17
12/17/17
12/17
17:17
12/17/17
17:17
Hot Stocks
Equinix announces acquisition of Metronode »

Equinix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$51.41

-1.08 (-2.06%)

17:11
12/17/17
12/17
17:11
12/17/17
17:11
Periodicals
Metlife failed to pay some pensions, Reuters reports »

Metlife failed to pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

GM

General Motors

$40.95

0.14 (0.34%)

17:06
12/17/17
12/17
17:06
12/17/17
17:06
Periodicals
GM facing $1B reckoning in ignition-switch settlement, WSJ reports »

General Motors faces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

TCEHY

Tencent

$50.31

-0.231 (-0.46%)

, BABA

Alibaba

$173.55

1.8 (1.05%)

16:58
12/17/17
12/17
16:58
12/17/17
16:58
Periodicals
Tencent to buy stake in supermarket chain, Bloomberg reports »

Tencent (TCEHY) to buy a…

TCEHY

Tencent

$50.31

-0.231 (-0.46%)

BABA

Alibaba

$173.55

1.8 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

16:50
12/17/17
12/17
16:50
12/17/17
16:50
Periodicals
Amazon in talks to acquire Sqrrl, Axios reports »

Amazon is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HUM

Humana

$253.64

3.03 (1.21%)

, KND

Kindred Healthcare

$8.60

0.45 (5.52%)

16:48
12/17/17
12/17
16:48
12/17/17
16:48
Periodicals
Humana in talks to acquire Kindred Healthcare, Reuters reports »

Humana (HUM) is in…

HUM

Humana

$253.64

3.03 (1.21%)

KND

Kindred Healthcare

$8.60

0.45 (5.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.30

-1.89 (-3.77%)

16:39
12/17/17
12/17
16:39
12/17/17
16:39
Hot Stocks
Oracle buys Aconex for $1.2B »

Oracle announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.93

-4.38 (-7.64%)

16:35
12/17/17
12/17
16:35
12/17/17
16:35
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$19.71

0.03 (0.15%)

16:09
12/17/17
12/17
16:09
12/17/17
16:09
Hot Stocks
Valeant, subsidiary announce early tender results »

Valeant Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Dec

  • 18

    Jun

KMF

Kayne Anderson Midstream/Energy Fund

$13.78

0.09 (0.66%)

16:01
12/17/17
12/17
16:01
12/17/17
16:01
Hot Stocks
Kayne Anderson Midstream/Energy Fund announces distribution of 30c per share »

Kayne Anderson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KYN

Kayne Anderson MLP

15:59
12/17/17
12/17
15:59
12/17/17
15:59
Hot Stocks
Kayne Anderson MLP announces distribution of 45c per share for Q4 »

Kayne Anderson MLP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KED

Kayne Anderson Energy

$16.68

-0.01 (-0.06%)

15:56
12/17/17
12/17
15:56
12/17/17
15:56
Hot Stocks
Kayne Anderson Energy announces distribution 40c per share for Q4 »

Kayne Anderson Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KYE

Kayne Anderson Energy

$10.19

-0.01 (-0.10%)

15:53
12/17/17
12/17
15:53
12/17/17
15:53
Hot Stocks
Kayne Anderson Energy announces distribution of 25c per share for Q4 »

Kayne Anderson Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.93

-4.38 (-7.64%)

15:18
12/16/17
12/16
15:18
12/16/17
15:18
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

CBOE Holdings

$126.37

0.31 (0.25%)

11:22
12/16/17
12/16
11:22
12/16/17
11:22
Periodicals
CBOE should not be treated as 'set and forget,' Barron's says »

Bitcoin futures have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

11:17
12/16/17
12/16
11:17
12/16/17
11:17
Periodicals
Disney/Fox 'a murky web of deals within deals,' Barron's says »

Walt Disney's (DIS)…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.83

1.44 (2.08%)

10:53
12/16/17
12/16
10:53
12/16/17
10:53
Periodicals
Alaska air should bounce back in 2018, Barron's says »

While shares of Alaska…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

10:42
12/16/17
12/16
10:42
12/16/17
10:42
Periodicals
Spark Therapeutics selloff may be overdone, Barron's says »

Spark Therapeutics shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.